This tactic has been validated in cancer patients with mutations in breast cancer gene 1 (BRCA1) and BRCA2 by the success of single agent poly (ADP-ribose) polymerase (PARP) inhibitor therapy [17]. The gene discussed is BRCA1; the disease is cancer.